As on Wednesday, LENZ Therapeutics Inc (NASDAQ: LENZ) started slowly as it slid -5.33% to $25.04, before settling in for the price of $26.45 at the close. Taking a more long-term approach, LENZ posted a 52-week range of $16.53-$50.40.
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was -181.63%. Meanwhile, its Annual Earning per share during the time was -181.63%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -10.77%. This publicly-traded company’s shares outstanding now amounts to $28.59 million, simultaneously with a float of $27.86 million. The organization now has a market capitalization sitting at $783.50 million. At the time of writing, stock’s 50-day Moving Average stood at $32.41, while the 200-day Moving Average is $31.21.
LENZ Therapeutics Inc (LENZ) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. LENZ Therapeutics Inc’s current insider ownership accounts for 10.95%, in contrast to 91.18% institutional ownership. According to the most recent insider trade that took place on Nov 17 ’25, this organization’s Chief Commercial Officer sold 10,000 shares at the rate of 26.10, making the entire transaction reach 261,022 in total value, affecting insider ownership by 4,733.
LENZ Therapeutics Inc (LENZ) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.85 per share during the current fiscal year. LENZ Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -10.77% and is forecasted to reach -2.76 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 34.76% through the next 5 years, which can be compared against the -181.63% growth it accomplished over the previous five years trading on the market.
LENZ Therapeutics Inc (NASDAQ: LENZ) Trading Performance Indicators
Let’s observe the current performance indicators for LENZ Therapeutics Inc (LENZ). It’s Quick Ratio in the last reported quarter now stands at 12.63. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 44.77.
In the same vein, LENZ’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.11, a figure that is expected to reach -0.95 in the next quarter, and analysts are predicting that it will be -2.76 at the market close of one year from today.
Technical Analysis of LENZ Therapeutics Inc (LENZ)
Through scrutinizing the latest numbers posted by the [LENZ Therapeutics Inc, LENZ], it can be observed that its last 5-days Average volume of 0.69 million was better the volume of 0.49 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 10.81% While, its Average True Range was 32.75.
Raw Stochastic average of LENZ Therapeutics Inc (LENZ) in the period of the previous 100 days is set at 13.12%, which indicates a major rise in contrast to 3.67% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 2.02 that was lower than 2.37 volatility it exhibited in the past 100-days period.
